echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Novel bispecific antibody ABBV-383 shows initial efficacy in relapsed/refractory multiple myeloma

    J Clin Oncol: Novel bispecific antibody ABBV-383 shows initial efficacy in relapsed/refractory multiple myeloma

    • Last Update: 2022-09-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Multiple myeloma (MM) is the second most prevalent hematological malignancy worldwide


    ABBV-383, a B cell maturation antigen × CD3 T cell-binding bispecific antibody, has shown promising results in an ongoing first-in-human Phase I study in relapsed/refractory multiple myeloma (RRMM) result


    The study enrolled patients with RRMM who had received at least three previous lines of therapy (including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies) to receive intravenous infusion of ABBV-383 every 3 weeks


    As of January 8, 2022, a total of 124 patients (dose escalation [0.



    Among evaluable patients (n=122), the objective response rate (ORR) was 57%, and the very good partial response or better (≥VGPR) rate was 43%



    In conclusion, ABBV-383 was well tolerated in patients with RRMM, with an objective response rate of 68% at doses ≥ 40 mg


     

    Original source:

    D'Souza Anita, Shah Nina, Rodriguez Cesar et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.